54 related articles for article (PubMed ID: 19036077)
1. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response.
Parodi E; Rivetti E; Amendola G; Bisogno G; Calabrese R; Farruggia P; Giordano P; Matarese SM; Nardi M; Nobili B; Notarangelo LD; Russo G; Vimercati C; Zecca M; De Mattia D; Ramenghi U
Br J Haematol; 2009 Feb; 144(4):552-8. PubMed ID: 19036077
[TBL] [Abstract][Full Text] [Related]
2. Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura.
Celik M; Bulbul A; Aydogan G; Tugcu D; Can E; Uslu S; Dursun M
J Thromb Thrombolysis; 2013 Feb; 35(2):228-33. PubMed ID: 22956408
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial.
Heitink-Pollé KMJ; Uiterwaal CSPM; Porcelijn L; Tamminga RYJ; Smiers FJ; van Woerden NL; Wesseling J; Vidarsson G; Laarhoven AG; de Haas M; Bruin MCA;
Blood; 2018 Aug; 132(9):883-891. PubMed ID: 29945954
[TBL] [Abstract][Full Text] [Related]
4. Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants.
Bennett CM; Neunert C; Grace RF; Buchanan G; Imbach P; Vesely SK; Kuhne T
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28792679
[TBL] [Abstract][Full Text] [Related]
5. Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia.
Papagianni A; Economou M; Tragiannidis A; Karatza E; Tsatra I; Gombakis N; Athanassiadou-Piperopoulou F; Athanasiou-Metaxa M
J Pediatr Hematol Oncol; 2011 May; 33(4):265-9. PubMed ID: 21516022
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.
Bussel JB; Buchanan GR; Nugent DJ; Gnarra DJ; Bomgaars LR; Blanchette VS; Wang YM; Nie K; Jun S
Blood; 2011 Jul; 118(1):28-36. PubMed ID: 21502541
[TBL] [Abstract][Full Text] [Related]
7. Recommendations for the management of acute immune thrombocytopenia in children. A Consensus Conference from the Italian Association of Pediatric Hematology and Oncology.
Russo G; Parodi E; Farruggia P; Notarangelo LD; Perrotta S; Casale M; Cesaro S; Del Borrello G; Del Vecchio GC; Giona F; Gorio C; Ladogana S; Lassandro G; Marzollo A; Maslak K; Miano M; Nardi M; Palumbo G; Rossi F; Spinelli M; Tolva A; Saracco P; Ramenghi U; Giordano P
Blood Transfus; 2024 May; 22(3):253-265. PubMed ID: 37677093
[TBL] [Abstract][Full Text] [Related]
8. Advances in management of pediatric chronic immune thrombocytopenia: a narrative review.
Lee JM
J Yeungnam Med Sci; 2023 Jul; 40(3):241-246. PubMed ID: 36617702
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and safety of caplacizumab versus placebo in thrombotic thrombocytopenic purpura: a meta-analysis and systematic review based on randomized controlled trials.
Chen B; Li X; Xiao D; Raimundo RD; Zhou R; Lei Y
Ann Transl Med; 2022 Jun; 10(12):657. PubMed ID: 35845542
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rituximab for minors with immune thrombocytopenia: a systematic review and meta-analysis.
Qu M; Zhou J; Yang SJ; Zhou ZP
J Int Med Res; 2020 Oct; 48(10):300060520962348. PubMed ID: 33115308
[TBL] [Abstract][Full Text] [Related]
11. Updated international consensus report on the investigation and management of primary immune thrombocytopenia.
Provan D; Arnold DM; Bussel JB; Chong BH; Cooper N; Gernsheimer T; Ghanima W; Godeau B; González-López TJ; Grainger J; Hou M; Kruse C; McDonald V; Michel M; Newland AC; Pavord S; Rodeghiero F; Scully M; Tomiyama Y; Wong RS; Zaja F; Kuter DJ
Blood Adv; 2019 Nov; 3(22):3780-3817. PubMed ID: 31770441
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
Lucchini E; Zaja F; Bussel J
Haematologica; 2019 Jun; 104(6):1124-1135. PubMed ID: 31126963
[TBL] [Abstract][Full Text] [Related]
13. Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist.
Osman ME
Sudan J Paediatr; 2012; 12(2):60-4. PubMed ID: 27493347
[TBL] [Abstract][Full Text] [Related]
14. Childhood immune thrombocytopenia: Clinical presentation and management.
Faki Osman ME
Sudan J Paediatr; 2012; 12(1):27-39. PubMed ID: 27493327
[TBL] [Abstract][Full Text] [Related]
15. Medication Repurposing in Pediatric Patients: Teaching Old Drugs New Tricks.
Rumore MM
J Pediatr Pharmacol Ther; 2016; 21(1):36-53. PubMed ID: 26997928
[TBL] [Abstract][Full Text] [Related]
16. Romiplostim as a treatment for immune thrombocytopenia: a review.
Chalmers S; Tarantino MD
J Blood Med; 2015; 6():37-44. PubMed ID: 25632241
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.
Matsubara K; Takahashi Y; Hayakawa A; Tanaka F; Nakadate H; Sakai M; Maeda N; Oka T; Ishii E; Bessho F; Morimoto T; Goto H; Hashii Y; Hatakeyama N; Shirahata A; Imaizumi M
Int J Hematol; 2014 Apr; 99(4):429-36. PubMed ID: 24609717
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for children with immune thrombocytopenia: a systematic review.
Liang Y; Zhang L; Gao J; Hu D; Ai Y
PLoS One; 2012; 7(5):e36698. PubMed ID: 22666325
[TBL] [Abstract][Full Text] [Related]
19. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.
Patel VL; Mahévas M; Lee SY; Stasi R; Cunningham-Rundles S; Godeau B; Kanter J; Neufeld E; Taube T; Ramenghi U; Shenoy S; Ward MJ; Mihatov N; Patel VL; Bierling P; Lesser M; Cooper N; Bussel JB
Blood; 2012 Jun; 119(25):5989-95. PubMed ID: 22566601
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
